Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

TCTMD’s Top 10 Most Popular Stories for November 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2017

November 29, 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

November 14, 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

Pulmonary Artery Denervation With a Radiofrequency Catheter: PADN Study Results

Presentation TCT 2017

Pulmonary Artery Denervation With a Radiofrequency Catheter: PADN Study Results

Presenter: Irene M. Lang, Ehtisham Mahmud, Hang Zhang

November 01, 2017

Same-Day Discharge After PAD Procedures Safe in Elderly Patients

News Daily News

Same-Day Discharge After PAD Procedures Safe in Elderly Patients

October 09, 2017

TCTMD’s Top 10 Most Popular Stories for September 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2017

September 30, 2017

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

Presentation VIVA 2017

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

Presenter: Ehrin J. Armstrong

September 19, 2017

Mobile Health Technologies May Boost Diagnosis, Care for Patients With Structural Heart Disease

News Daily News

Mobile Health Technologies May Boost Diagnosis, Care for Patients With Structural Heart Disease

Yael L. Maxwell

September 15, 2017

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

September 15, 2017

VIVA: Could Population-Wide Screening Trial for AAA, PAD, and Hypertension Save Lives at Low Cost?

News Conference News ESC 2017

VIVA: Could Population-Wide Screening Trial for AAA, PAD, and Hypertension Save Lives at Low Cost?

August 28, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On, With Hotly Anticipated Trials

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

August 18, 2017

Aspirin Use by Elderly Patients After Vascular Events Linked to More Bleeding, Especially GI Bleeds

News Daily News

Aspirin Use by Elderly Patients After Vascular Events Linked to More Bleeding, Especially GI Bleeds

Michael O'Riordan

June 14, 2017

CMS Lauded for Coverage Decision on Supervised Exercise Therapy for PAD

News Daily News

CMS Lauded for Coverage Decision on Supervised Exercise Therapy for PAD

June 08, 2017

Most PAD Patients ‘Dramatically Undertreated’ With Preventive Meds, Lifestyle Counseling

News Daily News

Most PAD Patients ‘Dramatically Undertreated’ With Preventive Meds, Lifestyle Counseling

May 01, 2017

Rivaroxaban’s “Overwhelming” Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

News Daily News

Rivaroxaban’s ‘Overwhelming’ Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

February 08, 2017

Routine Screening of ABI to Identify PAD: Despite Guidelines, One Expert Asks Why Not?

News Conference News ISET 2017

Routine Screening of ABI to Identify PAD: Despite Guidelines, One Expert Asks Why Not?

February 06, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.